Rutinib Tablet 5 mg contains Ruxolitinib, an oral Janus kinase (JAK) inhibitor that is used in the treatment of certain myeloproliferative disorders and inflammatory conditions. By selectively targeting the JAK-STAT signaling pathway, Ruxolitinib helps regulate abnormal blood cell production and reduces inflammation associated with these disorders.

Rutinib is primarily indicated for adults with intermediate or high-risk myelofibrosis, polycythemia vera, or other conditions involving excessive or abnormal blood cell proliferation. This lower-dose formulation is typically prescribed for patients requiring careful titration, dose adjustments, or initial therapy to minimize side effects while maintaining efficacy.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Composition

• Ruxolitinib 5 mg per tablet

Mechanism of Action

Ruxolitinib inhibits JAK1 and JAK2 enzymes, which play a critical role in signaling pathways that regulate hematopoiesis (blood cell production) and immune responses. Through this inhibition, Rutinib:

• Reduces abnormal production of blood cells in myeloproliferative disorders

• Decreases inflammatory cytokine activity, helping to alleviate disease symptoms

• Controls splenomegaly (enlarged spleen) in myelofibrosis

• Modulates immune-mediated processes in select inflammatory conditions

By acting directly on the molecular pathways underlying disease, Rutinib provides symptom relief and helps improve overall patient outcomes.

Indications

Rutinib Tablet 5 mg is indicated for:

• Intermediate or high-risk myelofibrosis

• Polycythemia vera in patients resistant or intolerant to conventional therapy

• Certain other myeloproliferative disorders as determined by a specialist

• Off-label use in select inflammatory disorders under careful medical supervision

It is intended for adult use and must be prescribed and monitored by a physician experienced in hematologic or immunologic therapies.

Dosage and Administration

The standard starting dose is 5 mg orally twice daily, with adjustments made based on patient response, blood counts, and tolerability. Tablets should be swallowed whole with water and may be taken with or without food.

Patients should have regular monitoring of complete blood counts, liver function, and kidney function during therapy. Dose modifications may be necessary to manage side effects such as anemia, thrombocytopenia, or liver enzyme elevation. Therapy discontinuation should be gradual to avoid rebound symptoms.

Benefits

• Reduces excessive or abnormal blood cell production

• Alleviates symptoms such as fatigue, night sweats, and splenomegaly

• Improves quality of life in patients with myeloproliferative disorders

• Provides a convenient oral therapy option

• Allows for flexible dosing and gradual titration

Precautions

• Use with caution in patients with infections, liver or kidney impairment, or low blood cell counts

• Avoid live vaccines during treatment

• Patients should inform their physician about all concomitant medications to prevent interactions

• Not recommended during pregnancy or breastfeeding

  রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Possible Side Effects

Common side effects may include:

• Fatigue and headache

• Nausea or diarrhea

• Low blood counts, including anemia or thrombocytopenia

• Increased susceptibility to infections

Serious but rare adverse effects may include severe infections, liver toxicity, or excessive bleeding. Immediate medical attention is required for serious symptoms.

Storage

Store below 30°C in a dry place, protected from light and moisture. Keep out of reach of children.

Rutinib Tablet 5 mg provides targeted, effective therapy for myeloproliferative disorders, helping control abnormal blood cell production, reduce organ enlargement, and improve overall quality of life under specialist supervision.